Gilead Sciences (GILD) EBT (2009 - 2026)

Gilead Sciences has reported EBT for 18 years, with the latest figure at $2.6 billion in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 56.46% year-over-year to $2.6 billion; the trailing twelve-month figure through Mar 2026 stood at $10.7 billion (up 57.19% YoY), and the FY2025 full-year result was $9.8 billion, up 1319.71% from the prior year.
• EBT for Q1 2026 stood at $2.6 billion, up from $2.1 billion in the prior quarter.
• The five-year high for EBT was $3.6 billion in Q3 2025, with the low at -$4.5 billion in Q1 2024.
• Historically, EBT has averaged $1.5 billion across 5 years, with a median of $2.0 billion in 2022.
• Annual changes were most pronounced in 2023 — EBT surged 955.26% — and 2024, when it slumped 445.08%.
• Gilead Sciences' EBT stood at $2.0 billion in 2022, then decreased by 18.61% to $1.7 billion in 2023, then soared by 31.09% to $2.2 billion in 2024, then retreated by 4.11% to $2.1 billion in 2025, then rose by 24.16% to $2.6 billion in 2026.
• The last three EBT figures came in at $2.6 billion (Q1 2026), $2.1 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.